- Home
- GOF vs ADPT Comparison
GOF vs ADPT Comparison
Compare GOF & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOF
- ADPT
- Stock Information
- Founded
- GOF 2006
- ADPT 2009
- Country
- GOF United States
- ADPT United States
- Employees
- GOF N/A
- ADPT N/A
- Industry
- GOF Finance/Investors Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GOF Finance
- ADPT Health Care
- Exchange
- GOF Nasdaq
- ADPT Nasdaq
- Market Cap
- GOF 2.3B
- ADPT 2.6B
- IPO Year
- GOF N/A
- ADPT 2019
- Fundamental
- Price
- GOF $11.99
- ADPT $16.48
- Analyst Decision
- GOF
- ADPT Strong Buy
- Analyst Count
- GOF 0
- ADPT 10
- Target Price
- GOF N/A
- ADPT $16.60
- AVG Volume (30 Days)
- GOF 789.2K
- ADPT 1.9M
- Earning Date
- GOF 01-01-0001
- ADPT 11-05-2025
- Dividend Yield
- GOF 15.42%
- ADPT N/A
- EPS Growth
- GOF N/A
- ADPT N/A
- EPS
- GOF N/A
- ADPT N/A
- Revenue
- GOF N/A
- ADPT $252,754,000.00
- Revenue This Year
- GOF N/A
- ADPT $36.43
- Revenue Next Year
- GOF N/A
- ADPT $12.31
- P/E Ratio
- GOF N/A
- ADPT N/A
- Revenue Growth
- GOF N/A
- ADPT 42.57
- 52 Week Low
- GOF $10.96
- ADPT $4.27
- 52 Week High
- GOF $16.76
- ADPT $17.89
- Technical
- Relative Strength Index (RSI)
- GOF 25.63
- ADPT 57.73
- Support Level
- GOF $11.96
- ADPT $13.28
- Resistance Level
- GOF $13.35
- ADPT $14.24
- Average True Range (ATR)
- GOF 0.28
- ADPT 0.94
- MACD
- GOF -0.08
- ADPT -0.10
- Stochastic Oscillator
- GOF 0.85
- ADPT 70.02
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).